Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00242424 · ClinicalTrials.gov registry record · Phase 2

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age

A Phase 2 study of Inactivated Influenza Vaccine, sponsored by Seattle Children's Hospital.

Completed
Registry status
Phase 2
Development phase
1,375
Enrollment target
1
Study location

NCT00242424 is a Phase 2 study of Inactivated Influenza Vaccine that has completed, run by Seattle Children's Hospital. The registered enrollment target is 1,375 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00242424, a Phase 2 study of Inactivated Influenza Vaccine, has completed, sponsored by Seattle Children's Hospital.

COMPLETED
Registry status
Phase 2
Development phase
1,375 participants
Enrollment target
1
Study location

Study Summary

Study of the safety and immunogenicity (antibody producing capability) comparing inactivated influenza vaccine to placebo given to infants at 2 and 3 months of age. Infants will receive inactivated influenza vaccine at the same time as other vaccines on the routine immunization schedule. Infants will be randomized at enrollment to receive inactivated influenza vaccine or placebo at a 2:1 ratio. This study is double-blind, randomized, and placebo-controlled.

Interventions

  • BIOLOGICAL 2005-2006 trivalent inactivated influenza vaccine

Study Locations (1)

Washington

  • Seattle Children's Hospital and Regional Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 1,375 participants
Start Date 2005-09
Est. Completion 2007-09
Phase Phase 2

Sponsor

Seattle Children's Hospital

168 total trials

What the Registry Record Tells You About NCT00242424

The ClinicalTrials.gov registry entry for NCT00242424 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Inactivated Influenza Vaccine appearing as the primary indexed condition, and to 1 intervention - of which 2005-2006 trivalent inactivated influenza vaccine is the first listed.

NCT00242424 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00242424 about?

NCT00242424 is a clinical study titled "Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age". Study of the safety and immunogenicity (antibody producing capability) comparing inactivated influenza vaccine to placebo given to infants at 2 and 3 months of age. Infants will receive inactivated influenza vaccine at the same time as other vaccines on the routine immunization schedule. Infants wil...

What is the current status of trial NCT00242424?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,375 participants. The study started on 2005-09. Estimated completion is 2007-09.

What conditions does trial NCT00242424 study?

This clinical trial studies the following conditions: Inactivated Influenza Vaccine.

What interventions are being tested in trial NCT00242424?

The interventions under investigation include: 2005-2006 trivalent inactivated influenza vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00242424?

This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00242424 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.